A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
Completed · Phase 1 · NCT02009449
Conditions: Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma, Colorectal Carcinoma, Pancreatic Carcinoma, Non-small Cell Lung Carcinoma, Solid Tumors, Breast Cancer
At a glance
- Research payments reported, 2025
- $105,784
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 353
About the trial
- Sponsor
- Eli Lilly and Company (with ARMO BioSciences)
- Tested
- Pegilodecakin (drug), Paclitaxel or Docetaxel and Carboplatin or Cisplatin (drug), FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil) (drug), gemcitabine/nab-paclitaxel (drug), Capecitabine (drug), Pazopanib (drug), Pembrolizumab (drug), Paclitaxel (drug), nivolumab (drug), Gemcitabine/carboplatin (drug)
- Dates
- Started 2013-11-15; completion 2023-07-22
- Results posted
- Yes
This is a first-in-human, open-label, dose escalation study to evaluate the safety and tolerability of pegilodecakin in participants with advanced solid tumors, dosed daily subcutaneously as a monotherapy or in combination with chemotherapy or immunotherapy.
From ClinicalTrials.gov, last updated 2026-07-09. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $105,784 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Memorial Sloan-Kettering $105,784
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.